BioSpace News Archive

NGMedical GmbH, a medical device manufacturer exclusively focused on creating innovative technologies for spinal application, announces the launch of its new ART® Fixation System in Europe.

TauRx Pharmaceuticals Ltd, the global leader in tau-based research in Alzheimer’s, announced unblinding of initial data from completion of the randomised portion of their pivotal Phase 3 clinical trial, LUCIDITY.

AlzeCure Pharma AB announced that an abstract of its preclinical project TrkA-NAM against osteoarthritis pain and other severe pain conditions has been accepted for presentation at the IASP 2022 World Congress on Pain in Toronto, Canada.

LINDIS Biotech GmbH announces the online publication of an abstract presenting interim data from the Company’s Catunibla Phase I dose escalation trial with CATUMAXOMAB at the American Society of Clinical Oncology Annual Meeting.

HUTCHMED Limited announces that TAZVERIK® has been approved by the Health Commission and Medical Products Administration of Hainan Province to be used in the Hainan Boao Lecheng International Medical Tourism Pilot Zone, under the Clinically Urgently Needed Imported Drugs scheme, for the treatment of certain patients with epithelioid sarcoma and follicular lymphoma consistent with the label as approved by the U.S. Food and Drug Administration.

Beta Bionics, Inc. announces Dr. Roy W. Beck and investigators will host a session: The Insulin-Only Bionic Pancreas Pivotal Trial—Randomized Clinical Trial Results at 12:45 p.m. CDT on Friday, June 3, in Ernest N. Morial Convention Center Great Hall A in New Orleans during the American Diabetes Association 82nd Scientific Sessions.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced new data from Phase 3 studies demonstrating patients treated with TREMFYA® achieved consistent, long-term efficacy through two years across the domains of active psoriatic arthritis – including joint, skin, enthesitis,a dactylitis,b spinal pain and disease severityc endpoints – irrespective of baseline characteristics.

Neuronascent Inc, announced that the U.S. Food and Drug Administration granted “Orphan Drug Designation” for the company’s NNI-351 treatment of Fragile X Syndrome.

Cambrex announced the acquisition of Q1 Scientific – a leading provider of environmentally-controlled cGMP stability storage services for the pharmaceutical, medical device and life science industries, strategically located in Waterford, Ireland.

Biodesix, Inc. announced Scott Hutton, Chief Executive Officer of Biodesix, will present at the 42nd Annual William Blair Growth Stock Conference being held June 6-9, 2022 at the Lowes Chicago Hotel in Chicago, IL.